“…Diarrhea/colitis is commonly reported, evidenced by fluid filled colon, dilation, wall thickening and/or mesenteric hyperemia (63). In contrast, pneumatosis and periportal edema related to hepatic failure are rare events (63). It is worthwhile to mention that each of the EGFR TKIs toxicities can be seen in patients treated with these agents in other cancer settings (e.g., erlotinib treatment of pancreatic cancer; cetuximab (Erbitux; Bristol-Myers Squibb, New York, NY, USA) treatment of advanced squamous cell carcinoma of the head and neck) (6465).…”